vs
IHS Holding Ltd（IHS）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
IHS Holding Ltd的季度营收约是Orthofix Medical Inc.的1.2倍（$254.0M vs $219.9M），Orthofix Medical Inc.同比增速更快（2.0% vs 0.1%），IHS Holding Ltd自由现金流更多（$178.6M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -22.0%）
IHS Holding是全球规模领先的共享通信基础设施独立持有、运营及开发企业之一，也是全球第五大独立跨国通信铁塔企业，业务覆盖非洲与拉美地区，为当地通信网络部署提供关键的铁塔基础设施支持。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
IHS vs OFIX — 直观对比
营收规模更大
IHS
是对方的1.2倍
$219.9M
营收增速更快
OFIX
高出1.9%
0.1%
自由现金流更多
IHS
多$161.8M
$16.8M
两年增速更快
OFIX
近两年复合增速
-22.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $254.0M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | 83.6% | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 0.1% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IHSOFIX
| Q4 25 | $254.0M | $219.9M | ||
| Q3 25 | $455.1M | $205.6M | ||
| Q2 25 | $433.3M | $203.1M | ||
| Q1 25 | $439.6M | $193.6M | ||
| Q4 24 | $253.8M | $215.7M | ||
| Q3 24 | $420.3M | $196.6M | ||
| Q2 24 | $435.4M | $198.6M | ||
| Q1 24 | $417.7M | $188.6M |
净利润IHSOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $147.4M | $-22.8M | ||
| Q2 25 | $32.3M | $-14.1M | ||
| Q1 25 | $30.7M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $-205.7M | $-27.4M | ||
| Q2 24 | $-124.3M | $-33.4M | ||
| Q1 24 | $-1.6B | $-36.0M |
毛利率IHSOFIX
| Q4 25 | 83.6% | 71.1% | ||
| Q3 25 | 47.5% | 72.2% | ||
| Q2 25 | 51.3% | 68.7% | ||
| Q1 25 | 51.4% | 62.8% | ||
| Q4 24 | 72.1% | 69.0% | ||
| Q3 24 | 52.0% | 68.7% | ||
| Q2 24 | 52.5% | 67.8% | ||
| Q1 24 | 39.1% | 67.5% |
营业利润率IHSOFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | 35.1% | -8.3% | ||
| Q2 25 | 33.8% | -7.9% | ||
| Q1 25 | 37.1% | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | 29.9% | -9.6% | ||
| Q2 24 | 34.0% | -12.5% | ||
| Q1 24 | -1.7% | -15.6% |
净利率IHSOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | 32.4% | -11.1% | ||
| Q2 25 | 7.5% | -6.9% | ||
| Q1 25 | 7.0% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | -48.9% | -13.9% | ||
| Q2 24 | -28.5% | -16.8% | ||
| Q1 24 | -372.8% | -19.1% |
每股收益（稀释后）IHSOFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $0.44 | $-0.57 | ||
| Q2 25 | $0.10 | $-0.36 | ||
| Q1 25 | $0.10 | $-1.35 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | $-0.61 | $-0.71 | ||
| Q2 24 | $-0.36 | $-0.88 | ||
| Q1 24 | $-4.67 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $825.7M | $82.0M |
| 总债务越低越好 | $3.1B | — |
| 股东权益账面价值 | $-89.8M | $450.0M |
| 总资产 | $4.5B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IHSOFIX
| Q4 25 | $825.7M | $82.0M | ||
| Q3 25 | $647.6M | $62.9M | ||
| Q2 25 | $531.8M | $65.6M | ||
| Q1 25 | $629.0M | $58.0M | ||
| Q4 24 | $578.0M | $83.2M | ||
| Q3 24 | $397.5M | $30.1M | ||
| Q2 24 | $445.7M | $26.4M | ||
| Q1 24 | $333.2M | $27.0M |
总债务IHSOFIX
| Q4 25 | $3.1B | — | ||
| Q3 25 | $3.3B | $157.2M | ||
| Q2 25 | $3.2B | $157.0M | ||
| Q1 25 | $3.4B | $156.9M | ||
| Q4 24 | $3.3B | $157.0M | ||
| Q3 24 | $3.5B | $118.5M | ||
| Q2 24 | $3.6B | $118.0M | ||
| Q1 24 | $3.5B | $118.2M |
股东权益IHSOFIX
| Q4 25 | $-89.8M | $450.0M | ||
| Q3 25 | $38.1M | $442.5M | ||
| Q2 25 | $-98.4M | $458.3M | ||
| Q1 25 | $-184.4M | $458.3M | ||
| Q4 24 | $-314.4M | $503.1M | ||
| Q3 24 | $-284.7M | $525.9M | ||
| Q2 24 | $-308.3M | $546.0M | ||
| Q1 24 | $-163.2M | $570.3M |
总资产IHSOFIX
| Q4 25 | $4.5B | $850.6M | ||
| Q3 25 | $4.7B | $832.6M | ||
| Q2 25 | $4.5B | $837.2M | ||
| Q1 25 | $4.4B | $823.1M | ||
| Q4 24 | $4.2B | $893.3M | ||
| Q3 24 | $4.6B | $867.9M | ||
| Q2 24 | $4.5B | $882.0M | ||
| Q1 24 | $4.6B | $906.0M |
负债/权益比IHSOFIX
| Q4 25 | — | — | ||
| Q3 25 | 85.85× | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $246.9M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $178.6M | $16.8M |
| 自由现金流率自由现金流/营收 | 70.3% | 7.6% |
| 资本支出强度资本支出/营收 | 26.9% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $718.7M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流IHSOFIX
| Q4 25 | $246.9M | $27.7M | ||
| Q3 25 | $251.3M | $12.4M | ||
| Q2 25 | $237.7M | $11.6M | ||
| Q1 25 | $200.3M | $-18.4M | ||
| Q4 24 | $344.4M | $23.7M | ||
| Q3 24 | $174.5M | $11.7M | ||
| Q2 24 | $134.7M | $9.0M | ||
| Q1 24 | $75.8M | $-18.6M |
自由现金流IHSOFIX
| Q4 25 | $178.6M | $16.8M | ||
| Q3 25 | $189.2M | $2.5M | ||
| Q2 25 | $197.7M | $4.5M | ||
| Q1 25 | $153.2M | $-25.1M | ||
| Q4 24 | $282.9M | $15.2M | ||
| Q3 24 | $122.3M | $6.3M | ||
| Q2 24 | $74.2M | $-360.0K | ||
| Q1 24 | $14.8M | $-29.1M |
自由现金流率IHSOFIX
| Q4 25 | 70.3% | 7.6% | ||
| Q3 25 | 41.6% | 1.2% | ||
| Q2 25 | 45.6% | 2.2% | ||
| Q1 25 | 34.8% | -13.0% | ||
| Q4 24 | 111.5% | 7.0% | ||
| Q3 24 | 29.1% | 3.2% | ||
| Q2 24 | 17.0% | -0.2% | ||
| Q1 24 | 3.5% | -15.4% |
资本支出强度IHSOFIX
| Q4 25 | 26.9% | 4.9% | ||
| Q3 25 | 13.6% | 4.8% | ||
| Q2 25 | 9.2% | 3.5% | ||
| Q1 25 | 10.7% | 3.5% | ||
| Q4 24 | 24.2% | 4.0% | ||
| Q3 24 | 12.4% | 2.7% | ||
| Q2 24 | 13.9% | 4.7% | ||
| Q1 24 | 14.6% | 5.6% |
现金转化率IHSOFIX
| Q4 25 | — | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 7.36× | — | ||
| Q1 25 | 6.52× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IHS
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
